This report by Dotmatics, based on a study conducted by the American Chemical Society (ACS), explores the trends and needs in biotech and contract research organization (CRO) collaborations for outsourcing in early small molecule drug discovery. The survey results indicate that while compound synthesis remains the primary task outsourced, biotech companies are increasingly seeking help from multiple CROs for additional areas such as drug metabolism, pharmacokinetics studies, toxicology, and safety assessment. The report emphasizes the importance of optimizing the biotech-CRO relationship through improved project-data exchange and data management solutions to streamline processes and enhance collaboration efficiency in early drug discovery outsourcing.
